Background: Advanced glycation end products (AGEs) are assumed to be involved in the development of premature atherosclerosis in diabetic patients, and it has recently been suggested that AGEs play a role in the atherosclerotic process in general. No study has examined the effect of medical intervention on circulating AGEs. Objective: To investigate whether angiotensin-converting enzyme (ACE) inhibitor therapy can influence the circulating levels of AGEs. Methods: Forty-two patients (35 men, 7 women, mean age ± SD 66.5 ± 6.0 years) participating in the Heart Outcomes Prevention Evaluation (HOPE) study were examined. Of these, 24 had been randomized to treatment with the ACE inhibitor ramipril and 18 to placebo at the start of the study. Serum levels of AGEs were measured with a polyclonal anti-AGE antibody, using a competitive immunoassay, in samples obtained from the patients at baseline and after 54 months of follow-up. Results: The serum AGE levels (median and 5th to 95th percentile in parentheses) increased significantly in the placebo group from 4.6 (0.3–17.2) U/ml to 7.7 (4.3–23.2) U/ml (p < 0.005) and in the ramipril group from 5.8 (2.7–14.1) U/ml to 7.2 (2.4–21.0) U/ml (p < 0.005). The increase of serum AGEs was significantly lower in the ramipril group than in the placebo group (p < 0.05). Conclusions: The serum levels of AGEs increased in high-risk patients with coronary artery disease over a period of 4.5 years. As compared with placebo, ramipril gave a lower increase of serum AGEs. Interference with AGEs may be a mechanism by which ACE inhibitors have a protective effect in the development of atherosclerosis.

Journal Section:
Clinical Trial
Keywords:
Advanced glycation end products, Angiotensin-converting enzyme inhibitors, Ramipril, Coronary artery disease
This content is only available via PDF.
© 2003 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2003
You do not currently have access to this content.